Viruses for tumor therapy
/in International Publications, Newcastle Disease Virus /von 2014-03-12 / Cell Host Microbe 2014 Mar;15(3):260-5Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy
/in International Publications, Newcastle Disease Virus /von 2014-03-07 / Immunol. Lett. 2014 May-Jun;159(1-2):36-46Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2014-03-05 / Sci Transl Med 2014 Mar;6(226):226ra32Novel approaches and mechanisms of immunotherapy for glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2014-03-01 / Discov Med 2014 Mar;17(93):145-54Natural killer cells: the secret weapon in dendritic cell vaccination strategies
/in Dendritic Cells, International Publications /von 2014-03-01 / Clin. Cancer Res. 2014 Mar;20(5):1095-103
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution